In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a price target of $10.00. The company's shares closed last Wednesday at $1.37, close to its 52-week low of $1.27. According to TipRanks.com, Wolleben has 0 stars on 0-5 stars ranking scale with an average return of -24.9% and a 22.3% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $9.67.
https://www.tipranks.com/news/blurbs/jmp-securities-thinks-clearside-biomedicals-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Clearside Biomedical Charts.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Clearside Biomedical Charts.